Dieter Hoelzer mainly investigates Internal medicine, Acute lymphocytic leukemia, Immunology, Surgery and Oncology. Internal medicine connects with themes related to Gastroenterology in his study. His research in Acute lymphocytic leukemia intersects with topics in Survival rate, Philadelphia chromosome, Imatinib, Induction chemotherapy and Acute leukemia.
His work deals with themes such as Cancer research and Haematopoiesis, which intersect with Immunology. His studies deal with areas such as Pharmacotherapy, Immunophenotyping and Cohort as well as Oncology. In his research on the topic of Leukemia, Myeloid is strongly related with Myeloid leukemia.
His primary areas of study are Internal medicine, Immunology, Cancer research, Oncology and Leukemia. His Internal medicine research includes themes of Gastroenterology and Surgery. His Immunology research is multidisciplinary, incorporating perspectives in Haematopoiesis and Stem cell.
His research investigates the connection between Oncology and topics such as Minimal residual disease that intersect with issues in Adult Acute Lymphoblastic Leukemia. His research integrates issues of Myeloid, Molecular biology and BAALC in his study of Leukemia. His work carried out in the field of Acute lymphocytic leukemia brings together such families of science as Survival rate and Philadelphia chromosome.
The scientist’s investigation covers issues in Internal medicine, Oncology, Transplantation, Acute lymphocytic leukemia and Minimal residual disease. His studies deal with areas such as Gastroenterology, Surgery and Immunology as well as Internal medicine. His research investigates the connection between Immunology and topics such as Cancer that intersect with problems in Disease.
Dieter Hoelzer combines subjects such as Lymphoblastic Leukemia and Rituximab with his study of Oncology. His Transplantation research is multidisciplinary, relying on both Stem cell, Pediatrics, Phases of clinical research and Dasatinib. His work deals with themes such as Survival rate, Blinatumomab and Clinical trial, which intersect with Acute lymphocytic leukemia.
Dieter Hoelzer mainly focuses on Internal medicine, Acute lymphocytic leukemia, Transplantation, Immunology and Oncology. The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine. His study looks at the intersection of Acute lymphocytic leukemia and topics like Blinatumomab with T cell and Molecular Response.
His Transplantation research includes elements of Cytarabine and Retrospective cohort study. His work on Immunodeficiency as part of general Immunology study is frequently linked to Centrosome duplication, bridging the gap between disciplines. His Hematopoietic stem cell transplantation research incorporates elements of Chemotherapy and Minimal residual disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)
Birgit Assmus;Volker Schächinger;Claudius Teupe;Martina Britten.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla.
The New England Journal of Medicine (2006)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J Rummel;Norbert Niederle;Georg Maschmeyer;G Andre Banat.
The Lancet (2013)
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
Marion G Ott;Manfred Schmidt;Kerstin Schwarzwaelder;Stefan Stein.
Nature Medicine (2006)
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler.
Journal of Clinical Oncology (2011)
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease
Stefan Stein;Marion G. Ott;Stephan Schultze-Strasser;Anna Jauch.
Nature Medicine (2010)
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
D Hoelzer;E Thiel;H Loffler;T Buchner.
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
Oliver G. Ottmann;Brian J. Druker;Charles L. Sawyers;John M. Goldman.
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.
Monika Brüggemann;Thorsten Raff;Thomas Flohr;Nicola Gökbuget.
Modern Therapy of Acute Lymphoblastic Leukemia
Renato Bassan;Dieter Hoelzer.
Journal of Clinical Oncology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: